“Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy.”This prize is given to an author/ authors outside of America & Europe selected by a BJUI panel as the best paper in terms of quality and potential impact on practice.
The study was initially a concept put forward by Jeremy Grummet at a concept session during an ANZUP Annual Scientific Meeting in 2015. At the time we thought the idea was simple, but great, so ANZUP applied and was successful in receiving a Cancer Australia Grant.
Subsequently, site Principal Investigators Nick Buchan and Dickon Hayne recruited many of the trial participants, and Dickon was the lead author on the paper and accepted the award on behalf of the study team.
“Pain-Free TRUS B was a genuinely high quality randomised clinical controlled trial and represents a fantastic trans-Tasman effort and a real win for ANZUP,” says Dickon Hayne.
The study was conducted between January 2016 and November 2019 and enrolled 420 people across Australia and New Zealand.
The outcomes of the trial were promising and improvements were seen in patient-reported discomfort, overall experience, and willingness to undergo repeat biopsies.
This is a great achievement, for a simple, yet innovative idea that helped improve the patient experience of cancer care.
Source: ANZUP Cancer Trials Group Limited. 2023. ANZUP’s Pain-free TRUS B trial wins the BJUI Global Prize 2023 for article of the year [Press release]. https://anzup.org.au/news/anzups-pain-free-trus-b-trial-wins-the-bjui-global-prize-2023-for-article-of-the-year/.